Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Pathways reviewed by Gavathiotis, Evripidis (9686652)

DB_ID Name
9648002 RAS processing
9652169 Signaling by MAP2K mutants
9652817 Signaling by MAPK mutants
9656223 Signaling by RAF1 mutants
9726840 SHOC2 M1731 mutant abolishes MRAS complex function
6802957 Oncogenic MAPK signaling
9726842 Gain-of-function MRAS complexes activate RAF signaling
9753512 Signaling by RAS GTPase mutants
9660537 Signaling by MRAS-complex mutants

Details on Person Gavathiotis, Evripidis

Class:IdPerson:9686652
_displayNameGavathiotis, Evripidis
_timestamp2020-05-04 20:35:57
created[InstanceEdit:9686650] Rothfels, Karen, 2020-05-04
crossReference[DatabaseIdentifier:9686648] ORCID:0000-0001-6319-8331
firstnameEvripidis
initialE
surnameGavathiotis
(author)[InstanceEdit:9686656] Gavathiotis, Evripidis, 2020-05-04
[LiteratureReference:9686649] Current Insights of BRAF Inhibitors in Cancer
[LiteratureReference:9686653] New perspectives for targeting RAF kinase in human cancer
[LiteratureReference:9690171] An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
[LiteratureReference:9710645] Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
[Change default viewing format]